港股上市公司荣昌生物（09995.HK）今日盘中股价大涨9.49%，引起市场广泛关注。这一强劲反弹可能是对昨日大跌的技术性修正，同时也反映了生物科技板块整体向好的趋势。
据悉，荣昌生物昨日（4月7日）收盘时大跌18.49%，今日的显著反弹可能是投资者认为股价被超卖后的回补行为。值得注意的是，生物科技行业今日整体上涨1.64%，显示出该板块普遍获得资金青睐。行业内其他股票如维亚生物（01873.HK）、药明合联（02268.HK）和博安生物（06955.HK）等均呈现不同程度的上涨。
尽管荣昌生物最近的财报显示公司仍处于亏损状态，净亏损达15.86亿港元，但分析师对该股仍保持乐观态度。在所有15家参与评级的机构中，73%的券商给予买入建议，27%给予持有建议，无券商建议卖出。这种积极的分析师评级可能也在一定程度上支撑了股价的反弹。投资者在关注该股时，仍需谨慎评估公司的基本面和行业发展趋势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.